Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. - Wikidata - awgldk - TriplyDB

Predictive genetic testing for drug-induced liver injury: considerations of clinical utility.

Predictive genetic testing for drug-induced liver injury: considerations of clinical utility.

http://www.wikidata.org/entity/Q38031096

about

Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.Parsing interindividual drug variability: an emerging role for systems pharmacology.Drug-induced liver injury: what was new in 2013?Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.Human leukocyte antigen genetic risk factors of drug-induced liver toxicology.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.Impressions of pharmacogenomic testing among Certified Registered Nurse Anesthetists: a mixed-method study.Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis.Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.

P2860

Q26779078-5001D865-038F-451F-A7EC-A5B1C3F38EFD Q28080256-5AAF6167-ABB4-449B-BAF4-37E85C5D59A9 Q33784830-DFA356ED-D97B-496B-9442-91F4BC67DB0F Q35135974-7A1DA017-E806-4EF7-A5B4-FEFB4B150DF4 Q36417380-96F79E12-7C3B-4288-B0D8-E14219BD57FC Q38205591-6114CD99-FBED-4F45-BEFE-0611C3B1C7EA Q38207944-33656B33-2D48-4963-9880-138FCD273CE1 Q38285818-37E4BD77-E802-49EB-B35F-3B7F1D59C954 Q38391340-BB33BF11-17C8-47F8-AE80-EC9D02EE8835 Q38599575-A76CBCA9-F7EE-45BF-8C11-24B7F3BF4003 Q39882314-5FB5DD34-D3C7-4508-840B-EE22021B291A Q40512525-2927328E-90CE-4E83-8C8B-44317E1FFD8C Q41389082-0FE10C12-6042-44FD-8FB3-06521DA0526D Q44380493-EFB06C05-87C1-4F2F-B340-33515C5A86F6 Q47826173-6D91200E-A3FF-48DB-82EE-7DF7B3FB9A9D

P2860

Predictive genetic testing for drug-induced liver injury: considerations of clinical utility.

http://www.wikidata.org/entity/Q38031096

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Predictive genetic testing for ...... derations of clinical utility.

@en

type

label

Predictive genetic testing for ...... derations of clinical utility.

@en

prefLabel

Predictive genetic testing for ...... derations of clinical utility.

@en

P1433

Q38031096-9315F659-9FF2-49C0-8590-200E992D29AD

P1476

Q38031096-0A2522F8-ADA2-4424-B141-C9A4F09C5049

P2093

Q38031096-04074E7B-0681-4F35-A26E-1F61462D206D

P2860

Q38031096-022867A9-6657-4655-B9A0-FE8D7A4F1C0A

Q38031096-0E75461D-7575-4C8C-B94B-3E2B1F65CAA6

Q38031096-15446A7E-2551-4F82-9B24-7C03AA1C1A1E

Q38031096-1752F2F7-9A24-4777-BFC3-474E057AC124

Q38031096-1F99E8D1-ADE7-4A8B-A374-40DF778C920B

Q38031096-21333E81-6433-448B-9FDD-B50EEB09FB08

Q38031096-23AD4CFB-0F0B-4D22-B9CA-8D65A43FAE97

Q38031096-2E01B52A-6D62-4D7A-BBD3-4CCD2F9ABCC3

Q38031096-45B1CCDB-1E69-40A3-AABE-F1D9374E09D0

Q38031096-489B8883-3205-4921-BE86-E1016B94AC5F

P304

Q38031096-965C596B-2CB5-452A-8F59-92587AA93054

P31

Q38031096-48B342B1-E41E-4E32-BF39-C70B1312FA33

P356

Q38031096-1484F246-3DFC-4E85-B299-ACFE693C97DF

P407

Q38031096-166E1023-0425-46AD-87BA-514E969ABED3

P433

Q38031096-25E7947E-B1AF-4DAC-A1A0-BC4C953B4CA8

P478

Q38031096-5875992A-8F62-45ED-8565-C9D3E1AAC6AE

P50

Q38031096-A6873FD4-BA40-477F-84BB-52C4034BECA9

P577

Q38031096-D9902E8F-C480-4D96-85FC-E94E14D2DD33

P698

Q38031096-57307F2B-5D8B-49FC-9C17-302F5DD0B951

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Predictive genetic testing for ...... derations of clinical utility.

@en

P2093

A Alfirevic

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Personal omics profiling reveals dynamic molecular and medical phenotypes

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

HLA-B*5701 screening for hypersensitivity to abacavir.

The use of PCA3 in the diagnosis of prostate cancer.

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method

Causality assessment in drug-induced hepatotoxicity.

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.

The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile.

P304

376-380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.107

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Munir Pirmohamed

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22850601

http://www.w3.org/2001/XMLSchema#string